<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254380</url>
  </required_header>
  <id_info>
    <org_study_id>GL-LSPT1-3003</org_study_id>
    <nct_id>NCT04254380</nct_id>
  </id_info>
  <brief_title>Gan &amp; Lee Evaluation of New Biosimilar for Type 1 Lispro</brief_title>
  <acronym>GENTL 1</acronym>
  <official_title>An Open-label, Randomized, Multicenter, Phase 3 Study to Compare the Immunogenicity, Efficacy, and Safety of Gan &amp; Lee Insulin Lispro Injection to Humalog in Adult Subjects With Type 1 Diabetes Mellitus (T1DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gan and Lee Pharmaceuticals, USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gan and Lee Pharmaceuticals, USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      • To compare the immunogenicity of Gan &amp; Lee Insulin Lispro Injection and EU-authorized
      Humalog following treatment in adult subjects with T1DM

      Secondary Objectives:

        -  To evaluate the safety of Gan &amp; Lee Insulin Lispro Injection in comparison with that of
           EU authorized Humalog following treatment in adult subjects with T1DM

        -  To evaluate the efficacy of Gan &amp; Lee Insulin Lispro Injection in comparison with that
           of EU authorized Humalog following treatment in adult subjects with T1DM
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    GanLee cancelled study -FDA Draft Guidance: &quot;Clinical Immunogenicity Considerations for
    Biosimilar &amp; Interchangeable Insulin Products&quot; released 11/25/2019
  </why_stopped>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects who meet the eligibility criteria will be centrally randomized 1:1 in an open-label fashion to receive either Gan &amp; Lee Insulin Lispro Injection or Humalog for 26 weeks. Randomization will be stratified by country.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment developed AIAs or important increase in AIA titers</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The percentage of subjects in each treatment group who develop treatment induced AIAs, defined as newly confirmed positive AIA development or important (at least a 4-fold) increase in titers after baseline and up to visit Week 26.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with negative AIA at baseline who develop positive AIA after baseline</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The percentage of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline and up to visit Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with important increase in titers</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The percentage of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline and up to visit Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in AIA titers</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The mean change from baseline in each treatment group in AIA titers after baseline and up to visit Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with confirmed positive AIA who develop anti-insulin NAbs</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The percentage of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26 who develop any anti-insulin NAbs after baseline and up to visit Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with positive AIA after baseline</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The percentage of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of all treatment-emergent adverse events</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The incidence and severity of all treatment-emergent adverse events and the following subgroups:
Adverse events of special interest. Serious adverse events, including fatal events. Adverse events leading to termination of the study treatment and/or early withdrawal from the study.
Treatment-related adverse events. IP device-related adverse events. Injection site reactions. The incidence of clinically significant laboratory abnormalities. The incidence of clinically significant abnormalities in physical examination and vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c at visit Week 26</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>Change from baseline in HbA1c at visit Week 26 in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieve an HbA1c of ≤ 7.0% at visit Week 26</measure>
    <time_frame>Week 1 to Week 26</time_frame>
    <description>The number and percentage of subjects who achieve an HbA1c of ≤ 7.0% at visit Week 26 in each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Experimental: Gan &amp; Lee Insulin Lispro Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gan &amp; Lee Insulin Lispro Injection for subcutaneous injection, 100 U/mL, in a disposable multidose pen injector with a pre-filled 3-mL type I glass cartridge. Subjects randomized to the Gan &amp; Lee Insulin Lispro Injection group will participate in the study for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Humalog</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled). Subjects randomized to the Humalog group will participate in the study for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gan &amp; Lee Insulin Lispro Injection</intervention_name>
    <description>Route of administration: subcutaneous injection</description>
    <arm_group_label>Experimental: Gan &amp; Lee Insulin Lispro Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humalog</intervention_name>
    <description>Route of administration: subcutaneous injection</description>
    <arm_group_label>Active Comparator: Humalog</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or nonpregnant, non-lactating female subjects between the ages of 18 and 75
             years, inclusive.

          2. Female subjects of child-bearing potential, willing to use contraceptive method(s),
             agreed by the Investigator, to prevent pregnancy during the study.

          3. Ability to provide written, personally signed, and dated informed consent to
             participate in the study, in accordance with the ICH GCP Guideline E6 and all
             applicable regulations, before initiating any study related procedures.

          4. Ability to understand and fully comply with all study procedures and restrictions.

          5. A confirmed diagnosis of T1DM and who have been on an approved basal-bolus insulin
             regimen for at least 6 months prior to Screening. The type or brand of insulins should
             not have changed in the 6 months before Screening.

          6. Do not expect to change the brand or type of their basal insulin during the study.

          7. C-peptide ≤ 1.0 ng/mL

          8. HbA1c ≤ 10.0%

          9. Body mass index (BMI) ≥ 19 kg/m2 and ≤ 35 kg/m2

         10. Adherence to a prudent diet and exercise regimen recommended by the medical provider
             in accordance with local standard of care or American Diabetes Association
             recommendations, and willingness to maintain this regimen consistently for the
             duration of the study.

        Exclusion Criteria:

          1. Participation in another clinical study within 30 days or 5 half-lives of last dose of
             experimental medication before Screening, whichever is longer.

          2. Previous use of Gan &amp; Lee Insulin Lispro Injection.

          3. Use of insulin neutral protamine hagedorn or insulin detemir within 6 months prior to
             study entry.

          4. Current or expected use of an insulin pump or use of continuous glucose measurement to
             monitor blood glucose during the study.

          5. Diabetic ketoacidosis (DKA) within 6 months before Screening.

          6. Brittle T1DM within 1 year before Screening, defined as more than 2 hospitalizations
             related to diabetes mellitus (excluding hospitalizations for diagnostic purposes),
             and/or severe hypoglycemia for which the subject experiences severe cognitive
             impairment requiring external assistance for recovery.

          7. Renal replacement therapy required or with an estimated (or measured) glomerular
             filtration rate &lt; 15 mL/min (Modification of Diet in Renal Disease calculation).

          8. Any clinically significant cardiovascular (CV) or cerebrovascular event, e.g.,
             myocardial infarction (MI), acute coronary syndrome (ACS), recent revascularization
             (including coronary artery bypass graft procedures [CABG], percutaneous coronary
             intervention [PCI]), transient ischemic attack (TIA), or hemorrhagic or ischemic
             stroke within 3 months before Screening.

          9. History of congestive heart failure defined as New York Heart Association (NYHA) Stage
             III or IV.

         10. Inadequately controlled or unstable hypertension as defined by a systolic blood
             pressure (SBP) &gt; 160 mmHg or diastolic blood pressure (DBP) &gt; 100 mmHg at Screening
             and/or Randomization.

         11. Inadequately controlled thyroid disease, as reflected by abnormal TSH and free T4
             values. (Hypothyroid or hyperthyroid conditions should be resolved or stabilized
             before Screening according to local standard of care).

         12. Any clinically significant (in the opinion of the Investigator) hematology, chemistry,
             or urinalysis test results at Screening, including any liver function test &gt; 3X of the
             upper limit of normal (ULN) or bilirubin &gt; 1.5X of the ULN (subjects with elevated
             bilirubin due to Gilbert syndrome are eligible to participate, if such tests were
             performed in the past).

         13. Autonomic neuropathy resulting in a diagnosis of gastroparesis.

         14. Hemoglobin &lt; 12 g/dL for males or &lt; 11 g/dL for females at Screening.

         15. Hospitalization within the 14 days before Screening, or planned hospitalization at any
             time during the study.

         16. Newly prescribed or high-dose (60 mg/day prednisone or equivalent) treatment with
             glucocorticosteroids, immunosuppressants, or cytostatic agents due to disorders of the
             immunological system, such as rheumatoid arthritis, psoriasis, spondyloarthritis, and
             asthma, within 60 days before Screening (Medications under following scenario are
             allowed: chronically administered oral, inhaled, topical, or intra-articular
             corticosteroids at a stable dosage; stable therapy with disease modifying agents
             [e.g., methotrexate, sulfasalazine]; disease is inactive [e.g., remission, well
             controlled stable phase]; and no significant changes in treatment scheme are
             expected).

         17. History of human immunodeficiency virus (HIV) or Hepatitis B or Hepatitis C
             infections.

         18. Any unresolved infection or a history of active infection within 30 days before
             screening other than mild viral illness (as judged by the Investigator).

         19. Current use of other medications for diabetes treatment, such as dipeptidyl peptidase
             4 inhibitors (DPP4i), glucagon-like peptide 1 receptor agonists (GLP1-R), or sodium
             glucose cotransporter 2 inhibitors (SGLT2i) (See Appendix 1 [Section 16.1] for a list
             of prohibited medications).

         20. A history of alcohol use of more than two drinks a day on average for the last year,
             or a history of alcohol or substance abuse within 2 years before Screening.

         21. Previous (within 3 months before Screening) or anticipated treatment with interferons.

         22. History of malignancy (except for treated non-melanoma skin cancer and treated
             cervical adenocarcinoma in situ) within 5 years before Screening

         23. Receiving blood transfusion or undergoing plasmapheresis within 6 months before
             Screening.

         24. History of splenectomy.

         25. Intolerance or history of hypersensitivity to insulin lispro or any excipient of the
             study drugs.

         26. Any other clinically significant medical or psychiatric condition, or one requiring
             further evaluation that in the opinion of the Investigator could interfere with
             conduct of the study or interpretation of the data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Lu, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gan &amp; Lee Pharmaceuticals, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Research Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angel City Research, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Research Association</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills-Peninsula Health Services</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Access Research - Santa Clarita</name>
      <address>
        <city>Santa Clarita</city>
        <state>California</state>
        <zip>91321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Institute of America</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers - Longmont</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research of Greater New Haven</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Diabetes and Endocrine Care</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M &amp; O Clinical Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sweet Hope Research Specialty Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homestead Associates in Research</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Research of Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research - Pasco County</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Institute for Clinical Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ormond Beach Clinical Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research - Pinellas County</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Spring Hill</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health - Columbus Regional Medical Group Endocrine Consultants - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health - Columbus Regional Medical Group Endocrine Consultants</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest CRC</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <zip>60012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes and Endocrinology Research Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Diabetes Endocrinology Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay West Endocrinology Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BTC Network - Capital Diabetes and Endocrine Associates - Camp Springs</name>
      <address>
        <city>Camp Springs</city>
        <state>Maryland</state>
        <zip>20746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine &amp; Metabolic Consultants</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Research Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BTC Network - Garden State Endocrinology - Brick</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Endocrine Group, LLP</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Diabetes and Endocrine Associates</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians Group</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians East - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carteret Medical Group - Morehead City</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Research Associates</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Your Diabetes Endocrine Nutrition Group, Inc.</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intend Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Stillwater</name>
      <address>
        <city>Stillwater</city>
        <state>Oklahoma</state>
        <zip>73111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Access Research - Warwick</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Diabetes &amp; Endocrine Consultants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Medical Specialists</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology - Central Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Medical Research Institute</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic - Kelly Lane</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research of San Antonio</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologie České Budějovice s.r.o</name>
      <address>
        <city>České Budějovice</city>
        <state>Jihocesky KRAJ</state>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diahaza s.r.o.</name>
      <address>
        <city>Holešov</city>
        <zip>769 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StefaMed</name>
      <address>
        <city>Hradec Králové</city>
        <zip>503 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milan Kvapil s.r.o</name>
      <address>
        <city>Praha 11</city>
        <zip>149 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabeteszentrum DO</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes-falkensee.de - Zentrum für klinische Studien</name>
      <address>
        <city>Falkensee</city>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RED-Institut GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>23758</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Praxis</name>
      <address>
        <city>Saarlouis</city>
        <zip>66740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lausmed Egeszsegugyi es Szolgaltato Kft.</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Kórház és Rendelőintézet</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trantor 99 Bt Anyagcsere Centrum</name>
      <address>
        <city>Budapest</city>
        <zip>1213</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Kenézy Gyula Egyetemi Kórház</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Békés Megyei Központi Kórház Pándy Kálmán Tagkórház</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanizsai Dorottya Kórház</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8801</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatokorhaz</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical-Expert Kutatási - Kísérleti és Szolgáltató Kft</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Kórház</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Gdanska Poradnia Cukrzycowa</name>
      <address>
        <city>Gdansk</city>
        <zip>80-858</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Kraków</name>
      <address>
        <city>Kraków</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne &quot;Diab-Endo-Met&quot;</name>
      <address>
        <city>Kraków</city>
        <zip>31-261</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CenterMed Lublin Sp. z o.o</name>
      <address>
        <city>Lublin</city>
        <zip>20 044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Lublin - Królewska</name>
      <address>
        <city>Lublin</city>
        <zip>20-109</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bogdan Walko Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Specjalistyczna MEDICA</name>
      <address>
        <city>Lublin</city>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Grunwald</name>
      <address>
        <city>Poznan</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMED Centrum Medyczne</name>
      <address>
        <city>Warszawa</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne K2J2</name>
      <address>
        <city>Wołomin</city>
        <zip>05-230</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalna Poradnia Diabetologiczna</name>
      <address>
        <city>Wrocław</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporów</name>
      <address>
        <city>Wrocław</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ferrol</name>
      <address>
        <city>Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario La Coruña (Gerencia de Gestión Integrada de A Coruña)</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Hospital de l'Esperit Sant</name>
      <address>
        <city>Santa Coloma de Gramenet</city>
        <zip>8923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuevas Tecnologías en Diabetes y Endocrinología</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 2, 2020</last_update_submitted>
  <last_update_submitted_qc>February 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Type 1</keyword>
  <keyword>Basal</keyword>
  <keyword>Insulin</keyword>
  <keyword>Lispro</keyword>
  <keyword>T1DM</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Insulin Dependent Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

